Study Evaluating Sorafenib Added to Standard Primary Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Less Than 60 Years of Age

NCT00893373 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

276

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia (AML)

Interventions

DRUG: sorafenib
DRUG: placebo

Sponsor

Technische Universität Dresden

Collaborators

[object Object]